Novavax has submitted its application to the U.S. FDA for its updated COVID-19 vaccine. Read more: ir.novavax.com/press-releases…

Novavax is attending the 2024 AANP National Conference in Nashville, TN this week! We look forward to connecting with the AANP community.

Novavax has filed with the European Medicines Agency (EMA) for its updated COVID-19 vaccine. Read more: novavax.investorroom.com/2024-06-24-Nov…

Today the U.S. Advisory Committee on Immunization Practices recommended use of 2024-2025 Formula for COVID-19 vaccines. Read the statement at: ir.novavax.com/press-releases…

Today, the first-ever doses of R21/Matrix-M™ Malaria Vaccine outside a clinical trial were administered in Cote d’Ivoire. We are both joyful at this milestone and hopeful for its potential to curb the impact of the disease. Congratulations to our partners and all involved in

Yesterday, the first commercial doses of the R21/Matrix-M™ malaria vaccine were administered to children in Cote d’Ivoire after decades of work by many developers and collaborators. Novavax celebrates this moment while noting there is much work ahead to curb the impact of

Malaria is one of the deadliest diseases in history and so common that a child under five years of age dies from malaria nearly every minute of every day. Learn more: novavax.com/insights/colla…

R21/Matrix-M™ Malaria vaccine administration expands: South Sudan has begun vaccinating eligible children to help protect against malaria as part of a 4-dose series. Learn more: gavi.org/news/media-roo…

For the first time, two vaccines are available to help protect children against malaria, which kills more than 600,000 people each year, 80% of whom are children under the age of 5. Learn more: novavax.com/insights/colla…

Novavax President and COO John Trizzino🇮🇱 will be interviewed by Premier Inc.'s Chief Commercial Officer Andy Brailo during Premier’s Breakthroughs '24 conference.

At Novavax, we're collaborating to help build a future free from the grip of malaria. Learn more: novavax.com/insights/colla…

We are proud to share Novavax’s participation in Citeline 's Navigating Clinical Trial Success: Biotech Lessons Learned roundtable. Learn from our Vice President of Clinical Development, Dr. Vivek Shinde, and other experts featured in the publication: discover.pharmaignite.com/novotech-us-rt…

“We need to rebuild confidence in the value and significance of a #COVID vaccine.” -Novavax President and COO, John Trizzino🇮🇱. Novavax was honored to attend Premier Inc.’s Breakthroughs ‘24 last week to discuss the future of vaccination. Thank you to all who joined! Learn more about

Novavax's conference call to discuss second quarter 2024 financial results and operational highlights is August 8 at 8:30 a.m. ET. Learn how you can join the call: ir.novavax.com/press-releases…

August is National Immunization Awareness Month! Here at Novavax, our focus is on developing life-saving vaccines to fight infectious diseases. Take the CDC adult vaccines quiz to learn more about what is recommended to protect you:  www2.cdc.gov/nip/adultimmsc… #NIAM

Novavax's conference call to discuss second quarter 2024 financial results and operational highlights is starting at 8:30 a.m. ET. Learn how you can join the call: ir.novavax.com/events

During the second quarter, Novavax continued executing against its four key priorities for the remainder of 2024. Take a look at our second quarter 2024 financial results and operational highlights: ir.novavax.com/press-releases…

Novavax has received Emergency Use Authorization from the U.S. #FDA for its updated COVID-19 vaccine in individuals aged 12 and older. Pre-filled syringes are expected to be available in thousands of locations across the U.S. in the coming days. Read the press release:

Novavax continues to monitor the performance of our 2024-2025 formula COVID-19 vaccine against new variants in non-clinical studies. Our data indicate that our vaccine provides cross-reactivity against the currently circulating variants.